Johnson & Johnson emerged as a bright spot, lifting its full-year guidance after second-quarter earnings surpassed analyst projections. The company’s oncology portfolio provided the necessary momentum to compensate for declining sales of Stelara, its former top-selling drug. The move signals a successful pivot for the pharmaceutical giant as it navigates a changing product landscape.

Contrasting this stability, Elevance Health saw its shares slide 9% despite a strong financial showing. The insurer beat earnings estimates and raised its full-year outlook for the second time in recent months, yet the market reacted negatively to the underlying data. Elsewhere, Germany’s Boehringer Ingelheim reported robust first-half sales driven by its diabetes medication, Jardiance, while the company prepares to enter the competitive U.S. obesity drug market.